A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J
Clin Lung Cancer. 2011 12 (3): 161-5

PMID: 21663858 · DOI:10.1016/j.cllc.2011.03.013

OBJECTIVES - Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings.

METHODS - Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m(2) intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician.

RESULTS - Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%.

CONCLUSIONS - Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC.

Copyright © 2011 Elsevier Inc. All rights reserved.

MeSH Terms (11)

Antineoplastic Combined Chemotherapy Protocols Camptothecin Carboplatin Female Humans Irinotecan Lung Neoplasms Male Middle Aged Neoplasm Staging Small Cell Lung Carcinoma

Connections (2)

This publication is referenced by other Labnodes entities: